Compare Natera Inc. Common Stock (NTRA) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Payoneer Global Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Payoneer Global Inc trades at $7.12 (market cap $2.42B). The key difference: Natera Inc. Common Stock is far larger — about 23.6× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Payoneer Global Inc for 62 Days on average.
| NTRA | PAYO | |
|---|---|---|
Market Cap | $57.03B | $2.42B |
Volume | 1,131,157 | 1,032,721 |
Sector | Health | Technology |
52-Week High | $425.64 | $7.18 |
52-Week Low | $179.42 | $4.27 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $56.18B | $2.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Payoneer Global (PAYO) trades at $7.15, up 0.42% with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, while revenue grew 10% excluding interest. Recent developments include the renewal of its Etsy partnership through 2029 and the announcement of a pending acquisition by Nuvei, creating significant investor interest and legal scrutiny.
The outlook remains cautiously optimistic with 60% analyst buy ratings, though earnings volatility and the pending acquisition create uncertainty. Key opportunities include strong B2B growth acceleration (48% YoY) and expanding international presence, while risks involve integration challenges with Nuvei and margin compression as net income margins decline from 16.8% in 2024 to 5.82% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
